Abstract
Agents that indiscriminately block endothelin receptors have been shown to cause moderate improvements in the outcomes of patients who have pulmonary arterial hypertension (PAH) as a complication of connective tissue disease (CTD). Girgis et al. investigated the effects of sitaxsentan, a selective endothelin receptor type A antagonist, in patients with CTD and comcomitant PAH. After 12 weeks of treatment, patients who received sitaxsentan showed more improvement from baseline compared with those receiving placebo in terms of exercise capacity, hemodynamics and physical-health-related quality of life. At the end of the extension study (median total follow-up 26 weeks), 16 of the 41 patients with CTD had an improvement of at least one New York Heart Association functional class compared with at the start of sitaxsentan therapy. The effects of sitaxsentan observed in the CTD group were comparable to those seen in the idiopathic PAH group. The authors concluded that treatment with sitaxsentan might be beneficial in patients with PAH associated with CTD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Humbert M et al. (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173: 1023–1030
Puri A et al. (2007) Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 4: 319–329
Sanchez O et al. (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130: 182–189
Avouac J et al. (2007) Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis [10.1136/ard.2007.077149]
Baughman RP et al. (2007) Six-minute walk test and health status assessment in sarcoidosis. Chest 132: 207–213
Merkel PA et al. (2003) Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 30: 1630–1647
Denton CP et al. (2007) Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis [10.1136/ard.2007.079921]
Allanore Y et al. (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58: 284–291
Acknowledgements
The summary was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Y Allanore has received honoraria (less than $10,000) for participation in meetings organized by Actelion and Encysive.
Rights and permissions
About this article
Cite this article
Allanore, Y. Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease?. Nat Rev Rheumatol 4, 238–239 (2008). https://doi.org/10.1038/ncprheum0790
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0790
